Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
Alpha Tau Medical Ltd ( (DRTS) ) has shared an update.
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
aQueen Mary University of London, Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Charterhouse Square, London, EC1M 6BT, UK bUniversity of Aberdeen ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY ® (piflufolastat F 18) with the potential for larger ...
An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results